Alder Biopharmaceuticals Receives $38,000,000 Series D Financing Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=fee9c9ee-d3f4-4af9-ab0f-fb4eb530bca6&Preview=1 - Date
4/19/2012 - Company Name
Alder Biopharmaceuticals - Mailing Address
11804 North Creek Parkway South Bothell, WA 98011 - Company Description
Alder Biopharmaceuticals uniquely identifies, develops, and manufactures novel antibody therapeutics to alleviate human suffering in the autoimmune and inflammatory disease areas. Alder’s management team combines decades of industry experience with a proven track record for identifying and developing novel antibody therapeutics. - Website
http://www.alderbio.com - Transaction Type
Venture Equity - Transaction Amount
$38,000,000 - Transaction Round
Series D - Proceeds Purposes
Proceeds of the financing will support clinical development of ALD518 and ALD403. ALD518, a monoclonal antibody to the pro-inflammatory cytokine IL-6, is currently being investigated in ongoing Phase 2 clinical studies in cancer related indications, which were retained by the company in its partnership with Bristol-Myers Squibb in 2009. - M&A Terms
- Venture Investor
Novo A/S - Venture Investor
Sevin Rosen Funds - Venture Investor
Ventures West - Venture Investor
WRF Capital - Venture Investor
H.I.G. Capital - Venture Investor
Delphi Ventures - Venture Investor
TPG Biotech
